Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice.

ABSTRACT:

Background

Gaps in current evidence and guidance leave clinicians with unanswered questions on the use of cladribine tablets for the treatment of multiple sclerosis (MS) in the era of the COVID-19 pandemic, in particular relating to COVID-19 vaccination.

Objective

We describe a consensus-based program led by international MS experts with the aim of supplementing current guidelines and treatment labels by providing timely recommendations relating to COVID-19 vaccination and the use of cladribine tablets in clinical practice.

Methods

A steering committee (SC) of 10 international MS experts identified 7 clinical questions to answer concerning the use of cladribine tablets and COVID-19 vaccination, which addressed issues relating to patient selection, timing and efficacy,

SUBMITTER: Rieckmann P 

PROVIDER: S-EPMC8655448 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature